LONDON, UK, ZUG, Switzerland and STOCKHOLM, Sweden – June 23, 2026 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully led a search for Cellcolabs and is pleased to announce the placement of Vincent Metzler, Ph.D., as Chief Executive Officer (CEO).
Cellcolabs is a Swedish biotechnology company specializing in the large-scale, industrial production of high-quality mesenchymal stromal cells (MSCs) to prevent and treat debilitating and life-threatening diseases.
Dr. Metzler joins the company at a critical milestone as it enters its next phase of growth, bringing more than 25 years of international experience across biotech and biopharma. His leadership background spans cell therapy, rare diseases, commercialization, fundraising, strategic partnerships, and company building. His extensive experience of scaling organizations will be highly valuable as Cellcolabs focuses on selected indications, advances its clinical studies, and scales its stem cell platform.
Maria Rankka, Chair of Cellcolabs, commented: “Cellcolabs has achieved a great deal in a short period of time and is now entering an exciting new phase. We see encouraging progress across our trials and growing potential within osteoarthritis and other selected indications, creating exciting opportunities for the company going forward. Vincent brings highly relevant experience as we continue focusing the company, strengthening partnerships and preparing for the next phase of development.”
“Partnering with Coulter Partners was essential to securing a leader of Vincent’s caliber. Their specialized international network and deep understanding of the advanced therapies landscape allowed them to identify an executive who perfectly combines a sophisticated scientific foundation with the commercial and fundraising track record needed to drive our regenerative medicine platform forward.”
Sabine Moravi, Associate Partner at Coulter Partners, added: “Cellcolabs is at an extraordinary inflection point, blending world-leading stem cell science with true industrial production capabilities. Finding a leader who could steer this transition required a rare mix of cell therapy expertise, strategic partnership experience, and a proven history of scaling international biopharma organizations. Vincent is an exceptional fit. His specialized expertise in cell therapy commercialization and corporate fundraising, notably demonstrated during his tenure at Kither Biotech and Atara Biotherapeutics, makes him uniquely qualified to lead Cellcolabs through this next high-growth chapter.”
---
Dr. Vincent Metzler, CEO of Cellcolabs
Vincent Metzler, Ph.D., is a highly seasoned life sciences executive with more than 25 years of international tenure across the biotechnology and biopharmaceutical sectors. Most recently, he operated an independent consultancy, advising emerging biotech firms on global fundraising and commercialization strategies. Prior to this, he served as CEO and Board Member of Kither Biotech, where he successfully restructured corporate strategy and closed a breakthrough €18.5 million Series B financing round.
Dr. Metzler’s extensive industry background includes prominent leadership roles at cell therapy and rare disease pioneers, including Atara Biotherapeutics, Wilson Therapeutics, Alexion Pharmaceuticals, Miltenyi Biotec, Roche, and Amgen. His core competencies encompass cross-border strategic alliances, lifecycle management, and corporate scale-up within regenerative medicine.
Dr. Metzler holds a Ph.D. in Molecular and Cellular Biology from the University of Bern.
[ENDS]
Notes to editors:
About Cellcolabs
Cellcolabs is a Swedish biotechnology company specializing in the large-scale production of mesenchymal stromal cells (MSCs). Cellcolabs’ mission is to prevent and treat disease through the GMP-certified production of high-quality stem cells. The MSCs produced by Cellcolabs for use in research and clinical studies at several leading university hospitals follow the same production protocol developed over 25 years by Professor Katarina Le Blanc at Karolinska Institutet. Cellcolabs was founded in 2021. The company’s investors include Titian Capital, Norrsken Launcher and prominent angel investors and family offices.
As part of its mission to accelerate the development of stem cell research and treatments, Cellcolabs sponsors clinical trials through its subsidiary, Cellcolabs Clinical.
About Coulter Partners
We are executive search and leadership development specialists working to build a better future. As advisors and consultants to companies at the cutting edge of Health, Science, and Technology, we are united by our mission to build teams that change the world. Operating uniquely as one global team, we have honed our expertise, platform, and data for over two decades, working across three continents, and in 40 countries. Applying what we learn through our work with boards, leadership teams, and investors in the world’s most innovative companies, we bring together and develop the right people at the right time to propel them to achieve their worthwhile goals.
Dr. Christelle Kerouedan
Director of Marketing & Communications
Coulter Partners